首页> 外文OA文献 >AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

【2h】

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

机译：AG-221，针对具有致癌IDH2突变的急性髓样白血病的一流疗法。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

International audience

机译：国际观众

著录项

作者
Yen, Katharine; Travins, Jeremy; Wang, F; David, Muriel D; Artin, Erin; Straley, Kimberly; Padyana, Anil; Gross, Stefan; DeLaBarre, Byron; Tobin, Erica; Chen, Yue; Nagaraja, Raj; Choe, S; Jin, Lei; Konteatis, Zenon; Cianchetta, Giovanni; Saunders, Jeffrey O; Salituro, Francesco G; Quivoron, Cyril; Opolon, Paule; Bawa, Olivia; Saada, Véronique; Paci, Angelo; Broutin, Sophie; Bernard, Olivier A; De Botton, Stéphane; Marteyn, Benoît S; Pilichowska, Monika; Xu, YingXia; Fang, C; Jiang, Fan; Wei, Wei; Jin, Shengfang; Silverman, Lee; Liu, Wei; Yang, Hua; Dang, Lenny; Dorsch, Marion; Penard-Lacronique, Virginie; Biller, Scott A; Su, SM;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations [J] . Yen Katharine, Travins Jeremy, Wang Fang, Cancer discovery. . 2017,第5期

机译：Ag-221，靶向急性髓性白血病的一类课程治疗，涉及致癌IDH2突变
2. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations [J] . Yen Katharine, Travins Jeremy, Wang Fang, Cancer discovery. . 2017,第5期

机译：AG-221，靶向急性髓鞘白血病的一级疗法治疗，涉及致癌IDH2突变
3. Targeted Metabolomic Profiling in Acute Myeloid Leukemia with IDH2(R140) and IDH2(R172) Mutations [J] . Hlavackova Alzbeta, Vydra Jan, Chrastinova Leona, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：患有IDH2（R140）和IDH2（R172）突变的急性髓性白血病中的靶向代谢物分析
4. Chemical proteomic identification of targets for antibody-drug conjugate based therapy in acute myeloid leukemia [C] . V. Strassberger, T. Fugmann, D. Neri American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2012

机译：基于抗体药物缀合物的靶向急性髓性白血病疗法的化学蛋白质组学鉴定
5. Therapeutic Targeting of the Interleukin 1 Receptor Accessory Protein (IL1 RAP) Reveals Novel Oncogenic Functions in Acute Myeloid Leukemia [D] . Mitchell, Kelly. 2018

机译：白细胞介素1受体辅助蛋白（IL1 RAP）的治疗靶向揭示急性髓细胞白血病中的新型致癌功能。
6. Combination targeted therapy to disrupt aberrant oncogenic signaling and reverse epigenetic dysfunction in IDH2- and TET2-mutant acute myeloid leukemia [O] . Alan H Shih, Cem Meydan, Kaitlyn Shank, -1

机译：联合靶向疗法可破坏IDH2和TET2突变的急性髓细胞白血病的异常致癌信号和逆向表观遗传功能障碍
7. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. [O] . Yen, Katharine, Travins, Jeremy, Wang, F, 2017

机译：AG-221，针对具有致癌IDH2突变的急性髓样白血病的一流疗法。
8. Chemotherapy in a Transplantable Myeloid Leukemia in Brown Norway Rats: Studies on BNML as a Model for Human Acute Myeloid Leukemia [R] . Golly, L. P. 1980

机译：Brown Norway大鼠可移植骨髓性白血病的化疗：BNmL作为人类急性髓性白血病模型的研究

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅